Ariad’s current market value is at the low end of what Credit Suisse analysts say it would cost to acquire the company. Ariad has been in business for 24 years and boasts 380 employees and one approved cancer drug. In a research note today, Credit Suisse said that “based on consensus forecasts we’d expect a Baxalta offer for Ariad at a 30-to-50 percent premium to Thursday’s pre-bid-report close.”
In the same note, analysts said they “lack insight into whether a deal will take place” but that it fits with Baxalta’s focus on cancer and hematology drugs.
The deal is notable since Baxalta, which is based in Illinois, has been building a 500-employee R&D facility in Kendall Square, also home to Ariad. It also comes as Baxalta itself is being pursued by Shire Pharmaceuticals (Nasdaq: SHPG), which recently saw a $30 billion bid for Baxalta rejected
Rosenblatt raises their NQ tgt to $13 from $10 as they are seeing big improvements in NQ Mobile's new mgmt execution capability and internal operations in the last two quarters. Firm believes co will be more aggressively and committed to buying back stock. Firm also believe Showself, as the core business of NQ, will become a growth driver and we model $90M in rev and $17M in net profit in 2016; also, firm expects $180M in revenue and $40M in net profits in 2017. Showself currently has 4.1M monthly active users, 10 times more than a year ago.
UPDATE: 21Vianet Group (VNET) Reports Q2 Loss Per Share of RMB0.28, Lowers FY Revenue Outlook
4:12 PM ET, 08/26/2015 - StreetInsider
(Updated - August 26, 20154:18 PM EDT)
21Vianet Group (NASDAQ: VNET) reported Q2 EPS of (RMB0.28), versus (RMB0.16) reported last year. Revenue for the quarter came in at RMB866.8 million, versus RMB658 million reported last year. 21Vianet Group sees Q3 2015 revenue of RMB900-940 million. FY revenue is seen at RMB3.58B-$3.68 billion vs prior guidance of RMB3.91B-4.11 billion.